EA199800754A1 - Противопатогенные пептиды и композиции, их включающие - Google Patents
Противопатогенные пептиды и композиции, их включающиеInfo
- Publication number
- EA199800754A1 EA199800754A1 EA199800754A EA199800754A EA199800754A1 EA 199800754 A1 EA199800754 A1 EA 199800754A1 EA 199800754 A EA199800754 A EA 199800754A EA 199800754 A EA199800754 A EA 199800754A EA 199800754 A1 EA199800754 A1 EA 199800754A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amino acid
- peptides
- possess
- acid residues
- hemolytic
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title 1
- 150000008574 D-amino acids Chemical group 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000001461 cytolytic effect Effects 0.000 abstract 2
- 230000002949 hemolytic effect Effects 0.000 abstract 2
- 150000008575 L-amino acids Chemical group 0.000 abstract 1
- 108010036176 Melitten Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010037075 Protozoal infections Diseases 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 abstract 1
- CTVQQQPWNOVEAG-QDOPKCMFSA-N pardaxin Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CN)C1=CC=CC=C1 CTVQQQPWNOVEAG-QDOPKCMFSA-N 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Обнаружено, что пептиды, которые обладают суммарным положительным зарядом и не обладают или только частично обладают α-спиральной конфигурацией, обладают негемолитической селективной цитолитической активностью. Данные пептиды могут быть получены из природных пептидов, таких как пардаксин и мелиттин и их фрагментов, в которых L-аминокислотные остатки заменены на корреспондирующие D-аминокислотные остатки и вышеупомянутые циклические производные, или они представляют собой диастереомеры линейных пептидов, составленных из разных соотношений, как минимум, из одной положительно заряженной аминокислоты и, как минимум, из одной гидрофобной аминокислоты, в которой, по крайней мере, один из аминокислотных остатков представляет собой D-аминокислоту, и, предпочтительно, как минимум, одна треть данной последовательности составлена из D-аминокислотных остатков. Фармацевтические композиции, включающие негемолитические цитолитические пептиды, могут использоваться для лечения некоторых заболеваний, вызванных патогенами, включающими антибактериальные, грибковые, вирусные, микоплазменные и протозойные инфекции, и для лечения рака.Отчет о международном поиске опубликован 1997.09.25.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11722396A IL117223A0 (en) | 1996-02-22 | 1996-02-22 | Antipathogenic polypeptides and compositions comprising them |
| PCT/IL1997/000066 WO1997031019A2 (en) | 1996-02-22 | 1997-02-20 | Antipathogenic peptides and compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA199800754A1 true EA199800754A1 (ru) | 1999-10-28 |
Family
ID=11068576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA199800754A EA199800754A1 (ru) | 1996-02-22 | 1997-02-20 | Противопатогенные пептиды и композиции, их включающие |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6172038B1 (ru) |
| EP (1) | EP0904291A2 (ru) |
| JP (1) | JP2000506128A (ru) |
| KR (2) | KR19990087100A (ru) |
| CN (1) | CN1216549A (ru) |
| AU (1) | AU730069B2 (ru) |
| BR (1) | BR9707691A (ru) |
| CA (1) | CA2247025A1 (ru) |
| CZ (1) | CZ264398A3 (ru) |
| EA (1) | EA199800754A1 (ru) |
| IL (2) | IL117223A0 (ru) |
| NZ (1) | NZ331219A (ru) |
| WO (1) | WO1997031019A2 (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1252808A (zh) * | 1997-02-20 | 2000-05-10 | 耶达研究及发展有限公司 | 抗病原合成肽及包含该肽类的组合物 |
| US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| BR9912053A (pt) | 1998-07-13 | 2001-04-03 | Univ Texas | Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| MEP42108A (en) | 1998-10-23 | 2011-02-10 | Kiren Amgen Inc | Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| GB0005703D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
| IL139720A0 (en) * | 2000-11-16 | 2002-02-10 | Yeda Res & Dev | Diastereomeric peptides and pharmaceutical compositions comprising them |
| CA2529125A1 (en) * | 2003-06-19 | 2004-12-23 | Yeda Research & Development Co. Ltd. | Antimicrobial and anticancer lipopeptides |
| EP1773400A2 (en) | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutic peptides |
| AU2005319578A1 (en) * | 2004-11-24 | 2006-06-29 | Neopro Labs, Llc | Methods and compositions for treating conditions |
| WO2006128289A1 (en) * | 2005-06-02 | 2006-12-07 | University Of Manitoba | Use of brevinin-2r in the treatment of cancer |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| WO2007074457A2 (en) * | 2005-12-27 | 2007-07-05 | Yeda Research And Development Co. Ltd. | Histidine-containing diastereomeric peptides and uses thereof |
| CA2637221A1 (en) | 2006-02-10 | 2007-08-16 | Dermagen Ab | Novel antimicrobial peptides and use thereof |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| JP6205364B2 (ja) * | 2012-09-05 | 2017-09-27 | 株式会社メニコン | 薬物徐放性眼用レンズ及びその製造方法 |
| JP6093528B2 (ja) * | 2012-09-19 | 2017-03-08 | 株式会社ミルボン | スクリーニング方法 |
| US11103547B2 (en) | 2016-02-04 | 2021-08-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods for disrupting biofilms |
| GB2557654A (en) * | 2016-12-14 | 2018-06-27 | Uea Enterprises Ltd | Method for nucleic acid depletion |
| CN113528600A (zh) * | 2021-07-08 | 2021-10-22 | 石河子大学 | 一种利用沙门氏菌诱导蝇蛆制备抗菌肽的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5258454A (en) * | 1988-09-01 | 1993-11-02 | Riso National Laboratory | Peptide synthesis method and solid support for use in the method |
-
1996
- 1996-02-22 IL IL11722396A patent/IL117223A0/xx unknown
-
1997
- 1997-02-20 EP EP97904561A patent/EP0904291A2/en not_active Ceased
- 1997-02-20 WO PCT/IL1997/000066 patent/WO1997031019A2/en not_active Application Discontinuation
- 1997-02-20 JP JP9529954A patent/JP2000506128A/ja not_active Ceased
- 1997-02-20 CA CA002247025A patent/CA2247025A1/en not_active Abandoned
- 1997-02-20 CN CN97194000A patent/CN1216549A/zh active Pending
- 1997-02-20 BR BR9707691A patent/BR9707691A/pt unknown
- 1997-02-20 NZ NZ331219A patent/NZ331219A/xx unknown
- 1997-02-20 KR KR1019980706488A patent/KR19990087100A/ko not_active Application Discontinuation
- 1997-02-20 US US09/125,605 patent/US6172038B1/en not_active Expired - Fee Related
- 1997-02-20 AU AU17319/97A patent/AU730069B2/en not_active Ceased
- 1997-02-20 IL IL12573497A patent/IL125734A/xx not_active IP Right Cessation
- 1997-02-20 CZ CZ982643A patent/CZ264398A3/cs unknown
- 1997-02-20 EA EA199800754A patent/EA199800754A1/ru unknown
-
1998
- 1998-02-19 KR KR1019997007477A patent/KR20000071187A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990087100A (ko) | 1999-12-15 |
| WO1997031019A2 (en) | 1997-08-28 |
| KR20000071187A (ko) | 2000-11-25 |
| IL125734A (en) | 2005-08-31 |
| BR9707691A (pt) | 1999-07-27 |
| CA2247025A1 (en) | 1997-08-28 |
| US6172038B1 (en) | 2001-01-09 |
| IL125734A0 (en) | 1999-04-11 |
| EP0904291A2 (en) | 1999-03-31 |
| IL117223A0 (en) | 1996-06-18 |
| AU730069B2 (en) | 2001-02-22 |
| NZ331219A (en) | 2000-04-28 |
| CN1216549A (zh) | 1999-05-12 |
| CZ264398A3 (cs) | 1999-01-13 |
| WO1997031019A3 (en) | 1997-10-23 |
| JP2000506128A (ja) | 2000-05-23 |
| AU1731997A (en) | 1997-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA199800754A1 (ru) | Противопатогенные пептиды и композиции, их включающие | |
| EA199900752A1 (ru) | Противопатогенные синтетические пептиды и композиции, их включающие | |
| ES2178000T3 (es) | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. | |
| DE68916932D1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
| EA200400205A1 (ru) | Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток | |
| DE69835279D1 (de) | Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika | |
| DE69532996D1 (de) | Peptidanaloge des menschlichen basischen myelinproteins | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| DE60040623D1 (de) | Komplementäre, synthetische peptide und ihre nutzung in der ophthalmologie | |
| AR019066A1 (es) | Heliomicina, fragmentos de acidos nucleicos codificantes de la heliomicina y composiciones farmaceuticas que la contienen | |
| WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| DE3261304D1 (en) | Retro-inverso analogues of c-terminal penta and hexapeptides of substance p. | |
| ATE408685T1 (de) | Antimikrobielle peptide, abstammend von ubiquicidin | |
| HU9603312D0 (en) | Novel elastase inhibitors | |
| FR2446292B1 (ru) | ||
| IL139720A0 (en) | Diastereomeric peptides and pharmaceutical compositions comprising them | |
| ATE256145T1 (de) | Peptid analoge, die einen siebengliedrigen lactamring enthalten | |
| ATE452903T1 (de) | Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten | |
| SE9700301D0 (sv) | New compound | |
| ES2071038T3 (es) | Peptidos asociados al hiv. | |
| GB2335923A (en) | Amino-butyrate derivatives of venoms | |
| ATE193543T1 (de) | Antithrombotische peptide aus den wiederholten sequenzen des typs ii |